A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.

Wei YinDavid HanPolyna KhudyakovRhett BehrjeJoel PosenerAntonio LaurenzaDimitrios Arkilo

Published in: British journal of clinical pharmacology (2022)

TAK-041 was generally well tolerated in healthy volunteers and adults with schizophrenia. Further investigation of TAK-041 in individuals with schizophrenia is supported.

Keyphrases

bipolar disorder
open label
double blind
randomized controlled trial
placebo controlled